Moderna shares fall nearly 7% as upbeat forecasts and cancer vaccine data fail to buoy stock

Traders Union
All News
Stocks
Moderna slides 6.81% today on updates

Highlights

Moderna raised its 2026 revenue growth projection to 15% to 25%, up from its prior guidance of up to 10%.
A Phase III trial showed intismeran, Moderna's personalized cancer vaccine with Merck, cut melanoma recurrence or death by 42% when used with Keytruda.
Moderna stock now trades near $231.77 with technical momentum bullish, support at $230.26, resistance at $233.84, and a projected five-day range of $210.79 to $252.75.

Upward revenue forecast and vaccine progress sustain despite selling pressure

Moderna raised its 2026 revenue growth forecast to 15–25% during its Analyst Day, an increase from its previous outlook of up to 10%. Progress was reported with intismeran, its personalized cancer vaccine developed with Merck, as Phase III results showed a 42% reduction in melanoma recurrence or death when combined with Keytruda. The company also reported more than 110,000 vaccinations of its FDA-approved mRNA-based influenza vaccine, mFLUSIVA, and was announced for addition to the MSCI World Index. All updates were released as price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees a disconnect between Moderna’s bullish forecast and the market’s reaction. He points out that despite raised guidance and strong phase III data, the sharp price drop exposes persistent risk appetite weakness. Kharitonov notes the technical setup remains positive but warns selling pressure after news reveals sentiment fragility. He highlights that the downside gap and elevated volatility signal traders remain unconvinced. "In my view, traders should remain defensive until price reclaims $233.84 with conviction."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s raised revenue outlook and pipeline progress affirm strong long-term fundamentals. He notes the bullish structure remains intact, with shares above key moving averages reflecting robust institutional confidence. Karapetjanc expects further growth as new vaccine data and index inclusion attract additional flows. "I see this period of volatility as an opportunity — the market offers multiple setups for further upside as momentum rebuilds above $233.84."

Parshwa Turakhiya, analyst, highlights the clash between strong technical momentum and a sentiment-driven drop. He sees short-term setups forming near support at $230.26, with intraday volatility creating trading opportunities. Turakhiya emphasizes the stock’s neutral indicators, suggesting traders should watch for breakouts. "I’d look for a decisive move — whichever side of $230.26 or $233.84 breaks may set the tone for the next swing."

Bullish momentum holds above averages as volatility challenges intraday support

MRNA is trading above its 20-day ($230.15), 50-day ($198.32), and 200-day ($94.54) moving averages. This strong positioning marks persistent bullish momentum across all observed timeframes, with the 50-day average well above the 200-day, and immediate support forming at $230.26 and resistance at $233.84. Momentum indicators, including MACD and Average Directional Index (ADX), show continued buy strength. RSI, Stochastic RSI, and Commodity Channel Index (CCI) all register neutral, indicating no immediate overbought or oversold risks. The Bull/Bear Power (BBP) is positive, reflecting intraday buying dominance, while the Awesome Oscillator provides a neutral reading. Despite these positive structural signals, the stock opened with a downside gap and has been pressured toward session lows, with intraday volatility at 4.89%.

Previously it was reported that Moderna's technical outlook remained broadly constructive, with analysts highlighting persisting bullish trend conditions and no decisive breakdown. The current analysis adds new confirmation as shares continue to hold above key moving averages despite volatility, with a breakout above $233.84 marking the next upside trigger to monitor.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.